DelveInsight’s Atrial Fibrillation pipeline report covers the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Key Facts from the Atrial Fibrillation Pipeline Report
Get a detailed analysis of the pipeline landscape @ Atrial Fibrillation Pipeline Outlook
Atrial Fibrillation Overview
Atrial Fibrillation is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure, and other heart complications. During atrial fibrillation, the heart’s two upper chambers (the atria) beat chaotically and irregularly, out of sync with the two lower chambers (the ventricles).
Atrial Fibrillation Symptoms
Some people with atrial fibrillation have no symptoms and are unaware of their condition until a physical examination reveals it. Those who have atrial fibrillation symptoms may experience the following signs and symptoms: palpitations, which are sensations of a racing, uncomfortable, irregular heartbeat or a flip-flopping in your chest, weakness, decreased ability to exercise, Fatigue, lightheadedness, dizziness, shortness of breath, and chest pain are all symptoms of a heart condition.
Atrial Fibrillation Treatment
In hemodynamically unstable patients, immediate evaluation and treatment, including emergency cardioversion if necessary, are required. Treatment in stable patients is determined by the duration of atrial fibrillation and, during atrial fibrillation, the presence of underlying cardiac disease or other comorbidities. The treatment of AF presents three major therapeutic quandaries.
Atrial Fibrillation Pipeline Analysis: Drug Profiles
Gencaro: ARCA biopharma
Product Description
Gencaro (bucindolol hydrochloride) is a pharmacologically specific beta-blocker and mild vasodilator in a clinical trial to treat and prevent recurrent atrial fibrillation, or AF, in patients with heart failure with mid-range ejection fraction, or HFmrEF.
Phase II
NCT01970501: ARCA Biopharma launched the “GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure” trial in April 2014.
Atrial Fibrillation Pipeline Therapies and Key Companies
Find out the emerging therapies and companies @ Atrial Fibrillation Clinical Trials
Atrial Fibrillation Therapeutics Assessment
Scope of the Report
Coverage: Global
Atrial Fibrillation Key Players: Chong Kun Dang Pharmaceutical, Merz Pharma, ARCA biopharma, AbbVie, Novartis, HUYA Bioscience, Hanmi Pharmaceutical, Verseon, Vivasc Therapeutics, Espero BioPharma, among others
Atrial Fibrillation Pipeline Therapies: CKD-825, Botulinum toxin A, Gencaro, AGN-151607, HSY 244, HBI-3000, HIP-2001, VE 1902, CTP-Amio, ESP-001, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Atrial Fibrillation: Overview
4.
Pipeline Therapeutics
5.
Late Stage Products (Phase III)
6.
Mid Stage Products (Phase II/III)
7.
Mid Stage Products (Phase II)
8.
Early Stage Products (Phase I)
9.
Pre-clinical Stage Products
10.
Therapeutic Assessment
11.
Inactive Products
12.
Collaborations Assessment- Licensing / Partnering / Funding
13.
Atrial Fibrillation- Unmet Needs
14.
Atrial Fibrillation- Market Drivers and Barriers
15.
Appendix
16.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Key questions answered in the Atrial Fibrillation Pipeline Report
Related Reports
Atrial Flutter Market
DelveInsight’s “Atrial Flutter Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Atrial Flutter, historical and forecasted epidemiology, and the Atrial Flutter market trends in the 7MM.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/